Acadia rises on Nuplazid AD readout

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $3.14 (12%) to $28.57 after it said Nuplazid pimavanserin met the primary endpoint of a Phase II exploratory study to

Read the full 250 word article

User Sign In